Viable Cell Counts for E. coli ATCC 25922 treated with B0063 for the indicated time before washout, initial inoculum of ~108 CFU/ml. Impact of R327 on E. coli cell membranes after 30 minutes of ...
SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced its primary ...
Phase II trial assessed the efficacy and safety of RECCE ® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections ...
Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health problem ...
Recce Pharmaceuticals Ltd, a company developing new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral ...
Recce Pharmaceuticals is an ASX-listed technology company involved in the development and commercialisation of new classes of synthetic anti-infectives designed to address the urgent global health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results